Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

ESMO 2018

19 - 23 Oct 2018
Messe Munich, Munich, Germany
Videos
News
Results from CABOSUN, METEOR and JAVELIN trials in kidney cancer
Dr Toni Choueri - Dana-Farber Cancer Institute, Boston, USA
Results from CABOSUN, METEOR and JAVELIN trials in kidney cancer ( Dr Toni Choueri - Dana-Farber Cancer Institute, Boston, USA )
12 Nov 2018
Breast cancer highlights from ESMO 2018
Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium
Breast cancer highlights from ESMO 2018 ( Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium )
12 Nov 2018
Comment on 'Ovarian Cancer: An ESMO Guide for Patients'
Dr Nicoletta Colombo - Istituto Europeo di Oncologia, Milan, Italy
Comment on 'Ovarian Cancer: An ESMO Guide for Patients' ( Dr Nicoletta Colombo - Istituto Europeo di Oncologia, Milan, Italy )
1 Nov 2018
The IMpower-132 trial for non small cell lung cancer
Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer...
The IMpower-132 trial for non small cell lung cancer ( Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, US )
29 Oct 2018
ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD...
Prof Paolo Ascierto - Istituto Nazionale Tumori, Milan, Italy
ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD 1 refractory melanoma ( Prof Paolo Ascierto - Istituto Nazionale Tumori, Milan, Italy )
29 Oct 2018
Keynote lecture: Mutation signatures and targeting the DNA damage response
Prof Thomas Helleday - Sheffield Cancer Centre, Sheffield, UK
Keynote lecture: Mutation signatures and targeting the DNA damage response ( Prof Thomas Helleday - Sheffield Cancer Centre, Sheffield, UK )
29 Oct 2018
Dosing regiment in the combination of ipilimumab and nivolumab in stage III...
Dr Lisette Rozeman - Netherlands Cancer Institute, Amsterdam, Netherlands
Dosing regiment in the combination of ipilimumab and nivolumab in stage III melanoma ( Dr Lisette Rozeman - Netherlands Cancer Institute, Amsterdam, Netherlands )
29 Oct 2018
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in...
Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma ( Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany )
29 Oct 2018
Modern melanoma treatment in the UK
Dr Joseph Sacco - University of Liverpool, Liverpool, UK
Modern melanoma treatment in the UK ( Dr Joseph Sacco - University of Liverpool, Liverpool, UK )
26 Oct 2018
Current clinical landscape for ALK non-small cell lung cancer patients
Dr Riyaz Shah and Dr Maurice Perol
Current clinical landscape for ALK non-small cell lung cancer patients ( Dr Riyaz Shah and Dr Maurice Perol )
26 Oct 2018
Latest advances in treatment for ALK positive NSCLC
Prof Gordon McVie, Dr Lázaro Quintela
Latest advances in treatment for ALK positive NSCLC ( Prof Gordon McVie, Dr Lázaro Quintela )
26 Oct 2018
The case for biosimilars
Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany
The case for biosimilars ( Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany )
26 Oct 2018
Highlights in early non-metastatic NSCLC and thoracic tumours
Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain
Highlights in early non-metastatic NSCLC and thoracic tumours ( Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain )
26 Oct 2018
Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with...
Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve...
Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC ( Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France )
26 Oct 2018
Combination strategies of immunotherapy in breast cancer
Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy
Combination strategies of immunotherapy in breast cancer ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )
26 Oct 2018
Highlights in SCLC from ESMO 2018
Dr Noemi Reguart - University of Barcelona, Barcelona, Spain
Highlights in SCLC from ESMO 2018 ( Dr Noemi Reguart - University of Barcelona, Barcelona, Spain )
26 Oct 2018
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel...
Dr David R. Spigel - Tennessee Oncology, Nashville, USA
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC ( Dr David R. Spigel - Tennessee Oncology, Nashville, USA )
26 Oct 2018
Safety analysis of entrectinib for NTRK fusion tumours
Dr George D. Demetri - Harvard Cancer Center, Boston, USA
Safety analysis of entrectinib for NTRK fusion tumours ( Dr George D. Demetri - Harvard Cancer Center, Boston, USA )
26 Oct 2018
TRITON2: Evaluation of rucaparib in patients with metastatic castration...
Dr Josep Piulats - IDIBELL, Barcelona, Spain
TRITON2: Evaluation of rucaparib in patients with metastatic castration-resistant prostate cancer ( Dr Josep Piulats - IDIBELL, Barcelona, Spain )
26 Oct 2018
ASCEND-8: safety data of ceritinib with or without food in NSCLC
Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea
ASCEND-8: safety data of ceritinib with or without food in NSCLC ( Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea )
26 Oct 2018
CheckMate142: Checkpoint combination therapy in first-line colorectal cancer
Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA
CheckMate142: Checkpoint combination therapy in first-line colorectal cancer ( Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA )
26 Oct 2018
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer
Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer ( Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA )
26 Oct 2018
Lung highlights from ESMO 2018
Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy
Lung highlights from ESMO 2018 ( Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy )
26 Oct 2018
Erlotinib for neoadjuvant treatment of EGFR NSCLC
Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical...
Erlotinib for neoadjuvant treatment of EGFR NSCLC ( Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China )
26 Oct 2018
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in...
Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC ( Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France )
25 Oct 2018
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M...
Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer...
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC ( Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, USA )
25 Oct 2018
20 year followup on high-dose chemo with HSCT in high-risk breast cancer
Dr Tessa Steenbruggen - Netherlands Cancer Institute, Amsterdam, Netherlands
20 year followup on high-dose chemo with HSCT in high-risk breast cancer ( Dr Tessa Steenbruggen - Netherlands Cancer Institute, Amsterdam, Netherlands )
25 Oct 2018
Opportunities for biosimilars in practice and education
Prof Diana Lüftner- Humboldt University, Berlin, Germany
Opportunities for biosimilars in practice and education ( Prof Diana Lüftner- Humboldt University, Berlin, Germany )
25 Oct 2018
Comment on the TRIBE-2 study on first and second-line treatment for metastatic...
Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation...
Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer ( Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy )
25 Oct 2018
VALENTINO: Maintenance therapy in advanced CRC
Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation...
VALENTINO: Maintenance therapy in advanced CRC ( Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy )
25 Oct 2018
Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic...
Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah
Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah )
25 Oct 2018
The Circulating Cell-Free Genome Atlas Study
Dr Minetta C. Liu - Mayo Clinic, Rochester, Minessota
The Circulating Cell-Free Genome Atlas Study ( Dr Minetta C. Liu - Mayo Clinic, Rochester, Minessota )
25 Oct 2018
The standard of care and progress so far with PARP inhibitors for ovarian cancer
Dr Susana Banerjee - The Institute of Cancer Research, London, UK
The standard of care and progress so far with PARP inhibitors for ovarian cancer ( Dr Susana Banerjee - The Institute of Cancer Research, London, UK )
25 Oct 2018
Cardiac events in stage III NSCLC treated in daily clinical practice
Dr Juliette Degens - Academisch Ziekenhuis Maastricht, Maastricht, Netherlands
Cardiac events in stage III NSCLC treated in daily clinical practice ( Dr Juliette Degens - Academisch Ziekenhuis Maastricht, Maastricht, Netherlands )
25 Oct 2018
Ceritinib and ribociclib in ALK-positive NSCLC
Dr Enriqueta Felip - Vall d'Hebron Institute of Oncology (VHIO), Barcelona...
Ceritinib and ribociclib in ALK-positive NSCLC ( Dr Enriqueta Felip - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
24 Oct 2018
Cemiplimab in patients with hepatocellular carcinoma
Dr Michael J. Pishvaian - Georgetown University, Washington, USA
Cemiplimab in patients with hepatocellular carcinoma ( Dr Michael J. Pishvaian - Georgetown University, Washington, USA )
24 Oct 2018
Updates from the EMBRACA trial for advanced breast cancer
Prof Hope Rugo - University of California, San Francisco, USA
Updates from the EMBRACA trial for advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )
24 Oct 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy
Dr Linda M. Henricks - Netherlands Cancer Institute, Amsterdam, Netherlands
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy ( Dr Linda M. Henricks - Netherlands Cancer Institute, Amsterdam, Netherlands )
24 Oct 2018
Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for...
Dr Maria Vittoria Dieci - University of Padua, Padova, Italy
Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2 positive breast cancer ( Dr Maria Vittoria Dieci - University of Padua, Padova, Italy )
24 Oct 2018
Liquid biopsy as a monitoring tool for the benefit of chemotherapy...
Dr Laura Bonanno - University of Padova, Padova, Italy
Liquid biopsy as a monitoring tool for the benefit of chemotherapy-immunotherapy in aNSCLC ( Dr Laura Bonanno - University of Padova, Padova, Italy )
24 Oct 2018
Comment on the Every Woman Study
Clara MacKay - World Ovarian Cancer Coalition, Canada
Comment on the Every Woman Study ( Clara MacKay - World Ovarian Cancer Coalition, Canada )
24 Oct 2018
Key developments in prostate cancer
Prof Nicholas James, Prof Karim Fizazi, Prof Matthew Smith, Prof Álvaro Pinto...
Key developments in prostate cancer ( Prof Nicholas James, Prof Karim Fizazi, Prof Matthew Smith, Prof Álvaro Pinto and Dr Mark Beresford )
22 Oct 2018
Therapeutic targeting at a pre-metastatic stage for brain metastases from lung...
Dr Sheila Singh - McMaster University, Ontario, Canada
Therapeutic targeting at a pre-metastatic stage for brain metastases from lung cancer ( Dr Sheila Singh - McMaster University, Ontario, Canada )
22 Oct 2018
Recent advances in CNS tumour management
Prof Joan Seoane - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Recent advances in CNS tumour management ( Prof Joan Seoane - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
22 Oct 2018
Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer
Dr Myriam Chalabi - Netherlands Cancer Institute, Amsterdam, Netherlands
Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer ( Dr Myriam Chalabi - Netherlands Cancer Institute, Amsterdam, Netherlands )
22 Oct 2018
Updates in head and neck cancers
Prof Jean-Pascal Machiels - University Clinic Saint-Luc, Brussels, Belgium
Updates in head and neck cancers ( Prof Jean-Pascal Machiels - University Clinic Saint-Luc, Brussels, Belgium )
22 Oct 2018
KEYNOTE022: Triplet therapy for BRAF melanoma
Prof Paolo Ascierto - Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale"...
KEYNOTE022: Triplet therapy for BRAF melanoma ( Prof Paolo Ascierto - Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Milan, Italy )
22 Oct 2018
First-line pembrolizumab for recurrent/metastatic head and neck squamous cell...
Prof Barbara Burtness - Yale University School of Medicine and Yale Cancer...
First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma ( Prof Barbara Burtness - Yale University School of Medicine and Yale Cancer Center New Haven, USA )
22 Oct 2018
SPLENDOUR: Added denosumab in first line adv NSCLC treatment
Dr Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne...
SPLENDOUR: Added denosumab in first line adv NSCLC treatment ( Dr Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )
22 Oct 2018
Women 4 Oncology: Advancing the careers of female oncologists
Dr Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne...
Women 4 Oncology: Advancing the careers of female oncologists ( Dr Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )
22 Oct 2018
Cisplatin superior to cetuximab for HPV oropharyngeal cancer
Prof Hisham Mehanna - University of Birmingham , Birmingham, UK
Cisplatin superior to cetuximab for HPV oropharyngeal cancer ( Prof Hisham Mehanna - University of Birmingham , Birmingham, UK )
22 Oct 2018
Cisplatin v cetuximab for HPV associated oropharyngeal cancer
Prof Hisham Mehanna - University of Birmingham , Birmingham, UK
Cisplatin v cetuximab for HPV associated oropharyngeal cancer ( Prof Hisham Mehanna - University of Birmingham , Birmingham, UK )
22 Oct 2018
Assessing radiotherapy for men with newly diagnosed metastatic prostate cancer
Dr Chris C. Parker - The Royal Marsden, London, UK
Assessing radiotherapy for men with newly diagnosed metastatic prostate cancer ( Dr Chris C. Parker - The Royal Marsden, London, UK )
22 Oct 2018
ESMO 2018: Melanoma highlights
Dr Teresa Amaral, Will Davies
ESMO 2018: Melanoma highlights ( Dr Teresa Amaral, Will Davies )
22 Oct 2018
IMpower130: PFS and safety of adding atezolizumab to first-line NSCLC therapy
Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy
IMpower130: PFS and safety of adding atezolizumab to first-line NSCLC therapy ( Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy )
22 Oct 2018
KEYNOTE048: First line pembrolizumab for recurrent or metastatic head and neck...
Prof Barbara Burtness - Yale Cancer Center, New Haven, USA
KEYNOTE048: First line pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma ( Prof Barbara Burtness - Yale Cancer Center, New Haven, USA )
22 Oct 2018
ESMO 2018: Highlights
Prof Gordon McVie , Will Davies
ESMO 2018: Highlights ( Prof Gordon McVie , Will Davies )
22 Oct 2018
IMpassion 130 trial results: Immunotherapy for metastatic breast cancer
Prof Peter Schmid - St Bartholomew Hospital London, UK
IMpassion 130 trial results: Immunotherapy for metastatic breast cancer ( Prof Peter Schmid - St Bartholomew Hospital London, UK )
22 Oct 2018
The TRIBE-2 study for colorectal cancer
Dr Chiara Cremolini - Università di Pisa, Pisa, Italy
The TRIBE-2 study for colorectal cancer ( Dr Chiara Cremolini - Università di Pisa, Pisa, Italy )
22 Oct 2018
Latest advances in precision medicine for prostate and bladder cancer
Prof Thomas Powles, Prof Matthew Galsky, Prof Bertrand Tombal
Latest advances in precision medicine for prostate and bladder cancer ( Prof Thomas Powles, Prof Matthew Galsky, Prof Bertrand Tombal )
22 Oct 2018
Advances in metastatic non small cell lung cancer
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Advances in metastatic non small cell lung cancer ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
21 Oct 2018
Detecting copy number alterations using a pre-natal test
Dr Liesbeth Lenaerts - KU Leuven, Leuven, Belgium
Detecting copy number alterations using a pre-natal test ( Dr Liesbeth Lenaerts - KU Leuven, Leuven, Belgium )
21 Oct 2018
Comment on the JAVELIN study: RCC immunotherapy
Prof John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands
Comment on the JAVELIN study: RCC immunotherapy ( Prof John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )
21 Oct 2018
Use of T-VEC in early metastatic melanoma
Ms Viola Franke - Netherlands Cancer Institute, Amsterdam, Netherlands
Use of T-VEC in early metastatic melanoma ( Ms Viola Franke - Netherlands Cancer Institute, Amsterdam, Netherlands )
21 Oct 2018
KEYNOTE 10: Pembrolizumab vs docetaxel for NSCLC
Dr Roy S. Herbst - Yale Cancer Centre, New Haven, USA
KEYNOTE 10: Pembrolizumab vs docetaxel for NSCLC ( Dr Roy S. Herbst - Yale Cancer Centre, New Haven, USA )
21 Oct 2018
PEACE: Collecting cancer tissue to solve the riddle of metastasis
Dr Mariam Jamal-Hanjani - UCL Cancer Institute and UCL Hospital, London, UK
PEACE: Collecting cancer tissue to solve the riddle of metastasis ( Dr Mariam Jamal-Hanjani - UCL Cancer Institute and UCL Hospital, London, UK )
21 Oct 2018
Expansion from CHECKMATE-032; nivolumab and ipilimumab for metastatic...
Dr Jonathan E. Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York...
Expansion from CHECKMATE-032; nivolumab and ipilimumab for metastatic urothelial carcinoma ( Dr Jonathan E. Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )
21 Oct 2018
Comment: Radiotherapy as a treatment option for metastatic prostate cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: Radiotherapy as a treatment option for metastatic prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
21 Oct 2018
JAVELIN Renal 101 trial: avelumab and axitinib for advanced renal cell carcinoma
Dr Robert J. Motzer - Memorial Sloan-Kettering Cancer Center, New York, USA
JAVELIN Renal 101 trial: avelumab and axitinib for advanced renal cell carcinoma ( Dr Robert J. Motzer - Memorial Sloan-Kettering Cancer Center, New York, USA )
21 Oct 2018
Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
Dr Robert J. Motzer - Memorial Sloan-Kettering Cancer Center, New York, USA
Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma ( Dr Robert J. Motzer - Memorial Sloan-Kettering Cancer Center, New York, USA )
21 Oct 2018
Survival results from STAMPEDE, radiotherapy for prostate cancer
Dr Chris C. Parker - The Royal Marsden, London, UK
Survival results from STAMPEDE, radiotherapy for prostate cancer ( Dr Chris C. Parker - The Royal Marsden, London, UK )
21 Oct 2018
The past, present and future of treating ovarian cancer
Dr Susana Banerjee - The Institute of Cancer Research, London, UK
The past, present and future of treating ovarian cancer ( Dr Susana Banerjee - The Institute of Cancer Research, London, UK )
21 Oct 2018
Comment on SOLO-1 for advanced ovarian cancer
Dr Jonathan Ledermann - University College London, London, UK
Comment on SOLO-1 for advanced ovarian cancer ( Dr Jonathan Ledermann - University College London, London, UK )
21 Oct 2018
Olaparib improves progression free survival up front in ovarian cancer
Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA
Olaparib improves progression free survival up front in ovarian cancer ( Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA )
21 Oct 2018
Comment on SOLO1 trial
Dr Jonathan Ledermann - University College London, London, UK
Comment on SOLO1 trial ( Dr Jonathan Ledermann - University College London, London, UK )
21 Oct 2018
A novel bifunctional fusion protein for combatting lung cancer
Dr Luis Paz-Ares - Hospital Universitario, Madrid, Spain
A novel bifunctional fusion protein for combatting lung cancer ( Dr Luis Paz-Ares - Hospital Universitario, Madrid, Spain )
21 Oct 2018
Comment on new treatment options for breast cancer
Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany
Comment on new treatment options for breast cancer ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )
20 Oct 2018
Early stage trials in immunotherapy and brain screening
Dr Elena Garralda - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Early stage trials in immunotherapy and brain screening ( Dr Elena Garralda - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
20 Oct 2018
Results from the PALOMA-3 trial for advanced breast cancer
Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA
Results from the PALOMA-3 trial for advanced breast cancer ( Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA )
20 Oct 2018
PALOMA-3 update, including OS data for HR positive HER2 negative breast cancer
Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA
PALOMA-3 update, including OS data for HR positive HER2 negative breast cancer ( Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA )
20 Oct 2018
Results from the SOLAR-1 trial for advanced breast cancer
Prof Fabrice André - Institut Gustave Roussy, Paris, France
Results from the SOLAR-1 trial for advanced breast cancer ( Prof Fabrice André - Institut Gustave Roussy, Paris, France )
20 Oct 2018
Economics and education around biosimilars
Prof Arnold G. Vulto - Erasmus MC, Rotterdam, Netherlands
Economics and education around biosimilars ( Prof Arnold G. Vulto - Erasmus MC, Rotterdam, Netherlands )
20 Oct 2018
Results from the IMpassion130 trial for triple-negative breast cancer
Prof Peter Schmid - St Bartholomew Hospital London, UK
Results from the IMpassion130 trial for triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew Hospital London, UK )
20 Oct 2018
Alpelisib and fulvestrant for advanced breast cancer: SOLAR-1
Prof Fabrice André - Institut Gustave Roussy, Paris, France
Alpelisib and fulvestrant for advanced breast cancer: SOLAR-1 ( Prof Fabrice André - Institut Gustave Roussy, Paris, France )
20 Oct 2018
Magnetic marker to judge pathological response to checkpoint therapy in melanoma
Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands
Magnetic marker to judge pathological response to checkpoint therapy in melanoma ( Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands )
20 Oct 2018
Rare EGFR mutations in lung adenocarcinoma
Prof Nicolas Girard - Institut Curie, Paris, France
Rare EGFR mutations in lung adenocarcinoma ( Prof Nicolas Girard - Institut Curie, Paris, France )
20 Oct 2018
Societal indicators of lung cancer screening behaviours
Prof Jean-François Morère - Hôpital Paul Brousse, Villejuif, France
Societal indicators of lung cancer screening behaviours ( Prof Jean-François Morère - Hôpital Paul Brousse, Villejuif, France )
20 Oct 2018
New therapeutic options in advanced and metastatic breast cancer
Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal
New therapeutic options in advanced and metastatic breast cancer ( Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal )
19 Oct 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation